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ABSTRACT 
The pandemic of Coronavirus Disease 2019 (COVID-19) has now affected the entire globe which was first surfaced in China in December 2019. In 
absence of effective therapy to manage COVID-19, repurposed therapies were being used to manage the condition. In view of an urgent need for 
definitive therapy, multiple repurposed drugs, and investigational drug candidates are being tried in clinical trials which may lead to the emergence 
of unknown short term and long term adverse drug reactions (ADRs), and hence it is crucial to assess the safety of the tried therapeutic 
interventions. The lag in the pharmacovigilance activities in the midst of this pandemic fosters under-reporting of ADRs. Difficulty in causality 
assessment due to factors like wide variations in clinical presentation, concomitant use of multiple drugs, associated comorbidities, drug-drug and 
drug-disease interaction which forestalls the appropriate causality assessment. Hydroxychloroquine, a repurposed antimalarial drug has been a 
part of hue and cry at present because of its in-question safety in patients with cardiac disorders. National and International Drug monitoring 
centers have stressed upon reporting of ADRs and to boost up the process and come up with various recommendations. We can overcome these 
issues by working cohesively, motivating HCPs and patients to report ADRs electronically, and by setting up dedicated pharmacovigilance rapid 
response team to tackle the issues at the earliest. 
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INTRODUCTION  
In current times of pandemic of Coronavirus Disease 2019 (COVID-
19), the entire globe is fighting a war against the severe acute 
respiratory syndrome coronavirus 2 (SARS-CoV-2) [1]. The COVID-
19 started in the Wuhan district of China with few cases of 
pneumonia having unfamiliar etiology and later it got spread to 
other countries of the world following which on March 11, 2020, it 
was declared as a global pandemic by the World Health Organization 
(WHO) [1–3]. As of 15th July 2020, a total of 12,964,809 confirmed 
cases of COVID-19, including 5,70,288 deaths have been confirmed 
by the WHO. As per WHO, the United States of America, Europe, 
Eastern Mediterranean, South-East Asia are worst hit by this 
pandemic apart from the reach-in African and Western Pacific 
regions [4]. COVID-19 most commonly presents with symptoms like 
fever, dry cough, and fatigue [5, 6]. Having diverse clinical 
presentations, it can also present with less common symptoms like 
myalgia, rhinorrhoea, headache, conjunctivitis, sore throat, 
diarrhoea, anosmia or ageusia, skin rash, or discoloration of fingers 
or toes [6–8]. The respiratory symptoms can range from mild flu to 
severe respiratory distress which can end up in progressive 
respiratory failure and sometimes death [7, 9]. The laboratory 
findings show lymphopenia, elevation in lactate dehydrogenase 
levels, and also associated with elevation of inflammatory markers 
such as C-reactive protein, D-dimer, ferritin, and interleukin-6 [9, 
10]. The radiology findings with computed tomography (CT) scans 
show bilateral pulmonary parenchymal ground-glass opacity along 
with pulmonary consolidation, and the presence of multiple 
bilaterally diffuse nodules with peripheral lung distribution [11, 12]. 
With the fast spread, increased morbidity, and mortality of the 
COVID-19, tremendous efforts are being made by multiple 
pharmaceutical giants to discover the drugs, vaccines, or other 
interventions for prophylaxis or treatment of the disease and to 
minimize and halt the associated damage it has caused to the entire 
globe [13]. Currently, there is no definitive treatment available for 
COVID-19 but on a positive note, recently a few vaccines for COVID-
19 have been approved in various parts of the world with 
emergency use authorization based on the limited data available. 
The entire world is trying out the medicines already in use for other 
diseases for its treatment but in the rush for treatments, we need to 
ensure not only the efficacy but also the safety of the drugs under 
trials. This paper discusses the scenario, impact, and challenges 
faced by pharmacovigilance monitoring during this pandemic.  
The operational structure of pharmacovigilance 
Pharmacovigilance (Pv) is a science of monitoring Adverse Drug 
Reactions (ADRs). WHO defines it as the “Science and activities 
relating to the detection, assessment, understanding, and prevention 
of adverse effects or any other possible drug-related problem” [14]. 
Pv not only monitors drugs but also the biological products, blood 
products, herbals, vaccines, medical devices, traditional and 
complementary medicines in view of identifying new ADRs 
associated with products and safeguard the patients [15–17]. The 
process of Pv includes primarily ADR data collection from the clinics 
or self-reporting of ADR which is communicated to ADR monitoring 
centers (AMCs) by filling up the ADR monitoring form/Individual 
Case Safety Report (ICSR) form which is reviewed, analyzed and 
causality assessment is done. If found authentic, the ADR is reported 
to the National Coordination Centre (NCC), Indian Pharmacopoeia 
Commission (IPC) through an online software called VigiFlow. At 
NCC, these ICSRs are reviewed to assess the quality of data and if 
found appropriate, it is forwarded to the “Uppsala Monitoring Centre 
(UMC), Sweden” which a global ADR monitoring center [16, 18]. 
UMC analyses the data and adds it up to the global database called 
“VigiBase”, which is maintained by UMC [19]. The NCC also sends 
these data to the Central Drugs Standard Control Organisation 
(CDSCO) from time to time or whenever enquired to monitor the 
safety of various drugs used in India [20, 21]. The data accumulated 
and generated from Pv is basically utilized in various ways like 
signal generation, post-approval regulation of the drug or vaccine, 
conducting continued medical education to update the healthcare 
professionals (HCPs) [18, 20]. WHO Programme for International 
Drug Monitoring with UMC has set up an online resource database 
named “VigiLyze” which delivers useful search and analysis 
functions along with providing a quick and clear overview of global 
VigiBase data in an instant graphical format [22]. 
Need of pharmacovigilance in era of Covid-19 
Pharmacovigilance monitoring is a crucial component in monitoring 
the safety of the therapies being given to COVID-19 patients. Though 
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numerous therapies are being used and tested, yet we lack robust data 
to answers the questions of effectiveness and safety by various drug 
candidates in view of the rapid drug discovery process at the time of 
this pandemic. In view of the dire need for an effective drug or vaccine 
against COVID-19, if we primarily focus the weight on the efficacy of 
the particular investigational candidate then it would be difficult to 
ensure the short and long-term safety of these agents. Many of the 
existing drugs including antimalarials like hydroxychloroquine and 
chloroquine, antivirals like lopinavir/ritonavir or remdesivir or 
favipiravir, antiprotozoals like ivermectin, immunomodulators like 
corticosteroids, and monoclonal antibodies like tocilizumab or 
sarilumab are being repurposed for the treatment of COVID-19 [13]. 
For gathering and pooling sufficient information regarding efficacy 
and ADRs of therapies used against COVID-19, it is essential to record 
and report all adverse events swiftly and correctly to the 
pharmacovigilance database which will initiate a timely review of 
reported data and signal generation or crucial safety data which the 
HCPs and prescribers are in urgent need of [19]. Currently, the reports 
of various suspected ADRs for these tried therapies that have reached 
VigiBase, have been published as a “Report from the WHO 
Collaborating Centre for International Drug Monitoring, Uppsala 
Monitoring Centre” which can help HCPs to be cautious and use these 
therapies rationally [23]. Presently, VigiLyze is also being used to 
visualize and analyze the safety data swiftly for drugs used in COVID-
19 [24]. Therefore, ensuring and supporting the collection of high-
quality data from adverse event reports is crucial for the safe use of 
pharmacotherapy in these patients.  
Reporting of adrs to NCC-IPC 
In India, the ADR can be reported by both HCPs and patients by any 
of the following means [25]: 
1) By filling up the Suspected ADR reporting form available at the 
PvPI, NCC(IPC) website which is available in English, Hindi, and 
other Vernacular Languages. 
2) Mobile application from Google play store named “ADRPvPI” 
3) Helpline Number Managed by NCC PvPI for ADR reporting for the 
HCPs and general public: 1800 180 3024. 
NCC-IPC has formulated a new "suspected ADR reporting form (for 
drugs used in prophylaxis/treatment of COVID-19) for voluntary 
reporting by HCPs". Apart from the usual information to be shared in 
the ADR form this new version has few newly added features to be 
reported like status on pregnancy, lactation, relevant tests/laboratory 
data with dates like chest X-Ray, ECG, biochemical examination, 
ophthalmological examination, test for COVID-19 (RT-PCR test or 
rapid antibody test), recent travel information, relevant 
medical/medication history, drug interaction, concomitant medication 
including a drug used for co-morbidities, and complementary 
medicines with therapy dates [26]. This additional information and 
knowledge regarding COVID-19 patients can help assist in the 
causality assessment in a better way. The above suspected ADR form 
for drugs used in COVID-19 can be downloaded from the URL: 
https://www.ipc.gov.in/images/Suspected_ADR_Reporting_Form-
converted_2020.pdf 
Importance of pharmacovigilance: a learning from hydroxyl-
chloroquine episode 
There was an increased demand for hydroxychloroquine (HCQ) and 
chloroquine (CQ) after the news of it being a magical drug [27]. In 
the initial in vitro studies, HCQ was found to be effective in the 
treatment of severe acute respiratory syndrome Coronavirus 2 
(SARS-CoV-2) [28, 29]. Even the initial studies have shown a benefit 
with HCQ and CQ in patients with SARS-CoV-2 [30, 31]. Few studies 
have shown that HCQ when given with azithromycin led to a 
reduction of the viral load in COVID-19 patients [32, 33]. Followed 
by various positive results, the Ministry of Health and Family 
Welfare, Government of India (GoI) with The Indian Council of 
Medical Research (ICMR) formulated guidelines dated 23rd Mar 2020 
to use HCQ in the following people [34]: 
1. All asymptomatic healthcare workers working towards 
containment and treatment of COVID-19 and working in non-COVID 
hospitals/non-COVID areas of COVID hospitals/blocks. 
2. Asymptomatic frontline workers, like surveillance workers posted 
in containment zones and paramilitary/police personnel involved in 
COVID-19 related activities. 
3. Asymptomatic household contacts of laboratory-confirmed cases.  
The recommendation also says that it should not be administered in 
known cases of retinopathy, hypersensitivity to HCQ or 4-
aminoquinoline compounds, G6PD deficiency, pre-existing 
cardiomyopathy, and cardiac rhythm disorders, and prophylaxis in 
children under 15 y of age and pregnancy and lactation [34].  
Later on, the COVID-19 Treatment Guidelines Panel, National 
Institute of Health (NIH) recommended against the use of CQ or HCQ 
for the treatment of COVID-19, except as a 'trial drug' in clinical 
trials [35]. A retrospective study in the USA did not identify any 
significant reduction in mortality or the need for mechanical 
ventilation with HCQ treatment with or without azithromycin [36]. 
Similar results were reported by WHO where it stopped the use of 
HCQ in SOLIDARITY trial concluding that HCQ did not reduce the 
mortality of hospitalized COVID-19 patients when compared with 
standard of care [37]. It was found that in patients with COVID-19, a 
combination of HCQ and azithromycin was associated with QTc 
prolongation are associated with cardiotoxicity (prolonged QT 
syndrome) with prolonged use particularly in patients with hepatic 
and renal dysfunction [38, 39]. Both the drugs have long half-lives 
hence even sequential use of them should be cautiously done [35]. At 
the time when all the evidence was against the use of HCQ, an 
observational study in India gave a ray of hope showing benefit with 
HCQ prophylaxis among HCPs [40]. Following this, ICMR constituted 
the National Task Force for COVID-19 which revised the guideline 
for HCQ use and recommended to be used only in the high-risk cases 
like [41]: 
1. Asymptomatic healthcare workers involved in the care of 
suspected or confirmed cases of COVID-19. 
2. Asymptomatic household contact of laboratory-confirmed cases. 
The guideline also mentions that the use of HCQ should only be done 
under the prescription of a registered medical practitioner and the 
patients are advised to contact the HCP in case of any adverse 
events. Along with chemoprophylaxis with HCQ, people should 
follow the recommendations to prevent the spread and worsening of 
the condition of the patients with COVID-19 [41]. Along with the 
prophylactic administration of HCQ, the self-reporting of ADRs to the 
pharmacovigilance centers or Pharmacovigilance Programme of 
India (PvPI) helpline/Application should be done [42].  
The above scenario of HCQ proves the importance of 
pharmacovigilance in any drug therapy or drug discovery. In the 
trials, HCQ had mixed results or even showed no benefits however it 
posed an enhanced possible risk increase in the number of ADRs or 
drug interactions which could worsen the condition of the patients. 
ICMR's recommendation to report all the ADRs is a crucial step as 
this will aid the policymakers to come down to a decision regarding 
a particular drug candidate whether new or old, to continue or 
discontinue the use of the particular drug or vaccine candidate in 
clinical care and research [23]. 
Covid and pharmacovigilance: challenges  
In current times, pharmacovigilance activities have taken a toll due 
to the pandemic of COVID-19. Due to the high infectivity of the virus, 
the usual contact with the patients and the healthcare professionals 
(HCPs)/residents has diminished to a great extent. The lockdown 
imposed along with working with a decreased workforce has made 
it difficult for the AMCs to report the ADRs at the same pace and 
quantity. Hence, it becomes a collaborative responsibility of the 
HCPs to come together and ensure proper acquisition and collection 
of ADRs with timely reporting and causality assessment in the AMCs. 
Proper reporting and expedited review of ADR reports will help in 
signal detection and generation of any substantial safety profile of 
the tried therapies. The causality assessment in COVID-19 patients 
seems to be a tedious task because of multiple reasons like a large 
array and variations in clinical signs and symptoms, evolving and 
newer manifestations, concomitant use of multiple drugs, presence 
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of other comorbidities and associated pharmacotherapies, drug-
drug and unknown drug-disease interaction in COVID-19 makes it 
difficult to deal with and may hamper the appropriate causality 
assessment. The difficulty in causality assessment and ensuring its 
quality has been an issue as mentioned in the "Report from the WHO 
Collaborating Centre for International Drug Monitoring, Uppsala 
Monitoring Centre" [23]. The above report also mentions the issue 
with restricted data available at present regarding this pandemic 
and the inconstancy or lack of certainty over other confounders (like 
the underlying disease). Confounders like extremes of age, 
pregnancy, and hepato-renal dysfunction can further make the 
causality assessment onerous. Apart from this, a large number of 
cases in the hospitals end up in enormous clinical workload which 
would again lead to a lack of strict ADR monitoring during the 
pandemic. In the midst of this pandemic, it is not always possible to 
do all the baseline blood tests before starting any 
investigational/off-label drug along with following up blood tests to 
monitor the toxicities which would again make it difficult to review 
and analyze the ADRs even if they are reported. Ministry of AYUSH 
under the Ministry of Health and Family Welfare, GoI has 
recommended self-care guidelines for preventive health measures 
and boosting immunity which includes various ayurvedic 
preparations and medicines to be used [43]. However, the guidelines 
also advise that these ayurvedic preparations do not claim to be a 
treatment for COVID-19 [43]. In a country like India, many patients 
do rely on traditional indigenous therapies like Ayurveda, Unani, 
Siddha, etc and many of these patients do not inform the treating 
physician about the use of these medicines. Literature also reveals 
that there is significant use of complementary and alternative 
therapies in India and patients tend to not inform their treating 
physician about their alternative medicine use [44, 45]. The use of 
these alternative medicines might increase the probability of drug 
interactions and worsen the case scenario. Hence, proper history 
taking along with appropriate information of all the medications and 
ADRs is crucial and must be gathered by HCPs for better patient 
management. 
Proposed steps to tackle the issue  
1. Promoting and supporting the AMCs and regional 
pharmacovigilance centers in the collection of ADRs 
2. Strict monitoring of the patients to generate ADR data and to 
combat under-reporting. 
3. Push for electronic or paperless reporting as it is the best possible 
way at present times. 
4. As a large part of the population resides in the rural areas so 
training and motivating the HCPs and patients in rural health and 
quarantine centers (for COVID-19) for reporting the ADRs via 
electronic means would generate a substantial amount of data  
5. Conducting webinars for the healthcare professionals to keep them 
motivated and updated with drug safety and pharmacovigilance. 
6. Dedicated pharmacovigilance rapid response team to collect, 
assess, and report the ADRs. 
CONCLUSION 
The current situation of the pandemic has posed challenges for the 
entire healthcare sector. The pharmacovigilance activities are also 
hampered. Several old, repurposed drugs and newer drugs are being 
administered to a large diversity of COVID-19 patients which could 
lead to numerous ADRs. ADR reporting is a crucial component to 
ensure the short and long-term safety of the administered therapy in 
these patients. With the current situation, it is quite difficult to collect 
and report ADRs caused by medications given to patients with COVID-
19. Hence it is crucial that HCPs and pharmacovigilance team need to 
unite to work cohesively and overcome the obstacles in the reporting 
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